4.7 Article

Development of 111In-labeled exendin(9-39) derivatives for single-photon emission computed tomography imaging of insulinoma

Journal

BIOORGANIC & MEDICINAL CHEMISTRY
Volume 25, Issue 4, Pages 1406-1412

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2016.12.051

Keywords

Exendin(9-39); Single-photon emission computed tomography; In-111; Glucagon-like peptide 1 receptor; Insulinoma

Funding

  1. Advanced Research for Medical Products Mining Program of the National Institute of Biomedical Innovation (NIBIO) of Japan
  2. Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED)
  3. Ministry of Health, Labor, and Welfare of Japan
  4. Center of Innovation Program from MEXT
  5. JST
  6. Japan Society for the Promotion of Science

Ask authors/readers for more resources

Insulinoma is a tumor derived from pancreatic beta-cells, and the resulting hyperinsulinemia leads to characteristic hypoglycemia. Recent studies have reported the frequent overexpression of glucagon-like peptide -1 receptor (GLP-1R) in human insulinomas, suggesting that the binding of a radiolabeled compound to GLP-1R is useful for the imaging of such tumors. Exendin(9-39), a fragment peptide of exendin-3 and -4, binds GLP-1R with high affinity and acts as an antagonist. Accordingly, radiolabeled exendin(9-39) derivatives have also been investigated as insulinoma imaging probes that might be less likely to induce hypoglycemia. In this study, we synthesized a novel indium-111 (In-111)-benzyl-diethylenetriaminepentaacetic acid (In-111-BnDTPA)-conjugated exendin(9-39), In-111-BnDTPA-exendin(9-39), and evaluated its utility as a probe for the SPECT imaging of insulinoma. natIn-BnDTPA-exendin(9-39) exhibited a high affinity for GLP-1R (IC50 = 2.5 nM), stability in plasma, and a specific activity that improved following reactions with a solvent and solubilizer. Regarding the in vivo biodistribution of In-111-BnDTPA-exendin (9-39) in INS-1 tumor-bearing mice, high uptake levels were observed in tumors (14.6%1D/g at 15 min), with corresponding high tumor-to-blood (T/B), tumor-to-muscle (T/M), and tumor-to-pancreas (T/P) ratios (T/B = 2.55, T/M = 22.7, T/P = 2.7 at 1 h). The pre-administration of excess nonradioactive exendin(9-39) significantly reduced accumulation in both the tumor and pancreas (76% and 68% inhibition, respectively) at I h after In-111-BnDTPA-exendin(9-39) injection, indicating that the GLP-1R mediated a majority of In-111-BnDTPA-exendin(9-39) uptake in the tumor and pancreas. Finally, In-111-BnDTPA-exendin(9-39) SPECT/CT studies in mice yielded clear images of tumors at 30 min post-injection. These results suggest that In-111-BnDTPA-exendin(9-39) could be a useful SPECT molecular imaging probe for the detection and exact localization of insulinomas. (C) 2017 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available